Printer Friendly

TECHNICLONE INTERNATIONAL CORP. ANNOUNCES THAT ALPHA THERAPEUTIC HAS MADE ITS SECOND MILESTONE PAYMENT FOLLOWING A MEETING WITH THE FDA

 TUSTIN, Calif., July 27 /PRNewswire/ -- Techniclone International (OTC Pink Sheets: TCLN) ("TCLN") announced today that Alpha Therapeutic Corp. ("Alpha Therapeutic") has made its second milestone payment following a Pre-IND Phase III meeting for LYM-1 with the FDA.
 Alpha Therapeutic also exercised its option to begin clinical trials of LYM-1 in Europe. Alpha Therapeutic plans to commence the European trial approximately six months after initiation of the United States trial.
 LYM-1 is a radioactive labeled monoclonal antibody which is designed to treat Non-Hodgkins B cell lymphoma. According to Lon H. Stone, president and chief executive officer of Techniclone, "The alliance between Alpha Therapeutic and Techniclone takes advantage of Techniclone's expertise in biotech research and production and Alpha Therapeutic's worldwide marketing capabilities and experience in managing clinical trials and working with the regulatory agencies in the U.S. and Europe."
 Techniclone is a research and development stage company and has concentrated its efforts on developing cancer detecting and cancer fighting monoclonal antibodies.
 -0- 7/27/93
 /CONTACT: Lon H. Stone, chairman and CEO of Techniclone, 714-838-0500/
 (TCLN)


CO: Techniclone International Corp.; Alpha Therapeutic Corp. ST: California IN: MTC SU: PDT

LM-MF -- LA016 -- 6002 07/27/93 07:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 27, 1993
Words:197
Previous Article:DATUM ANNOUNCES SECOND QUARTER RESULTS
Next Article:NORTH STAR UNIVERSAL, INC. ANNOUNCES SECOND QUARTER AND SIX MONTH 1993 RESULTS


Related Articles
NOVEL ANTI-CANCER DRUG LICENSED TO ALPHA THERAPEUTIC
TECHNICLONE INTERNATIONAL CORP. FINALIZES FINANCING AGREEMENT WITH MAJOR SHAREHOLDER
TECHNICLONE INTERNATIONAL CORP. ANNOUNCES IND FILING WITH U.S. FDA
TECHNICLONE INTERNATIONAL CORP. ANNOUNCES PRESENTATION ON RESULTS
TECHNICLONE INTERNATIONAL CORP. REPORTS CLINICAL TRIALS ALLOWED BY FDA
TECHNICLONE INTERNATIONAL CORP. ANNOUNCES GRANT OF EUROPEAN PATENT
TECHNICLONE INTERNATIONAL CORPORATION BEGINS LYM-1 RADIOLABELING MOVES A STEP CLOSER TO TREATMENT FOR NON-HODGKIN'S LYMPHOMA
TECHNICLONE INTERNATIONAL CORP. ANNOUNCES NRC LICENSING OF OKLAHOMA RADIO LABELING FACILITY
TECHNICLONE AND ALPHA THERAPEUTIC ANNOUNCE PATIENT ENROLLMENT IN PHASE III TRIAL OF ONCOLYM(TM) FOR TREATMENT OF NON-HODGKIN'S LYMPHOMA
Alpha Therapeutic Announces Completion of Dosimetry Study and Results of FDA Meeting

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters